HB 3008 revises Missouri’s pharmacy practice statutes by repealing and reenacting sections 338.010 and 338.055. The bill expands and clarifies what counts as the “practice of pharmacy,” including prescription-order handling, medication therapy management, compounding and dispensing, consultation, nicotine replacement therapy, HIV postexposure prophylaxis, and certain limited prescribing activities for minor, self-limiting, non-diagnostic, or emergency conditions. It also expressly authorizes pharmacists to order and administer certain FDA-approved vaccines to eligible patients, subject to board rules, training, observation, reporting, and emergency protocols.
The bill also updates the disciplinary and licensing framework for pharmacists and pharmacy-related licensees. It preserves board authority to deny, discipline, suspend, or revoke licenses for a wide range of misconduct, while adding specific language about standards of care, delegation, and joint rulemaking by the Board of Pharmacy and the Board of Registration for the Healing Arts. It further limits when health carriers may require physician-pharmacist written protocols and states that pharmacists may not independently diagnose or prescribe outside the bill’s enumerated exceptions. A notable provision bars discipline based solely on lawful dispensing of ivermectin or hydroxychloroquine in accordance with prescriber directions.
The bill’s impact on state law is to broaden pharmacist authority in several clinical and public-health areas while tightening the statutory boundaries around protocols, supervision, and professional discipline. It would affect pharmacists, physicians, health carriers, pharmacies, and the state boards that regulate pharmacy and healing arts, and it would require joint rulemaking for medication therapy services and vaccine administration. It also reinforces patient-notification and reporting requirements tied to the ShowMeVax immunization registry.
No committee transcript or vote record was provided, so there is no documented floor or committee sentiment to summarize. Based on the text alone, the bill appears generally supportive of expanded pharmacist practice and public-health access, but it also contains guardrails that reflect concern about scope of practice, physician oversight, and patient safety. The inclusion of the ivermectin and hydroxychloroquine non-discipline language suggests a specific point of controversy or legislative concern about pharmacist discretion versus prescriber authority.
HB 3008 would amend Missouri pharmacy law by redefining and expanding the statutory scope of pharmacy practice, authorizing additional pharmacist services, and revising disciplinary provisions under chapter 338. It would affect sections governing pharmacist licensure, medication therapy protocols, vaccine administration, reporting to the state immunization registry, and board enforcement authority, while also limiting independent pharmacist diagnosis and prescribing outside specified exceptions.
No votes or committee discussion were provided, so there is no recorded legislative sentiment to report. From the bill text, the measure appears to have a pro-pharmacy, pro-access orientation, especially regarding vaccines and medication therapy services, while also including restrictions and oversight provisions that suggest an effort to balance expanded authority with physician supervision and patient protections.
The main points of contention likely involve scope of practice and professional control: whether pharmacists should be allowed to prescribe or administer more medications and vaccines, how much authority should remain with physicians through written protocols, and whether health carriers can require those protocols. The bill also singles out ivermectin and hydroxychloroquine, prohibiting discipline for lawful dispensing under prescriber directions and limiting pharmacist challenges to efficacy, which suggests a likely dispute over pharmacist autonomy, prescriber judgment, and politically sensitive COVID-era treatments.